This is a phase I pharmacokinetic study of HIV positive patients stable on antiretroviral
therapy who will switch treatment when enrolled from nevirapine to rilpivirine. On day 60 of
the study the participants will attend clinic where they will have blood collected followed
by a lumbar puncture where cerebrospinal fluid will be collected to measure drug
concentration. The participants will then restart their original regime with nevirapine.